NCT05870462: Semaglutide and Vascular Regeneration
- State
- State not given
- Phase
- Phase 4
- People
- 100 planned
- Started
- 29 Apr 2023
- Primary completion
- Dec 2024
- Arms
- Semaglutide
- Results
- None posted
- 29 Apr 2023: Trial started
- 23 May 2023: Trial registered
A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set
Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.
Kind of treatment: Drug.
Also known as Arm 2 - DehydraTECH-semaglutide alone, Ozempic, Rybelsus, Semaglutide (Wegovy®), Semaglutide 1.0 mg, Semaglutide 2.4 mg, Semaglutide Injectable Product, Semaglutide Injectable Product (Wegovy and/or Ozempic), Semaglutide Pen Injector, Semaglutide, 1.34 mg/mL, Wegovy.
Registries searched: ClinicalTrials.gov, through 17 Nov 2026.